Dataset Information

Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection.

ABSTRACT: The COVID-19 pandemic is an unprecedented global challenge, and point-of-care diagnostic classifiers are urgently required. Here, we present a platform for ultra-high-throughput serum and plasma proteomics that builds on ISO13485 standardization to facilitate simple implementation in regulated clinical laboratories. Our low-cost workflow handles up to 180 samples per day, enables high precision quantification, and reduces batch effects for large-scale and longitudinal studies. We use our platform on samples collected from a cohort of early hospitalized cases of the SARS-CoV-2 pandemic and identify 27 potential biomarkers that are differentially expressed depending on the WHO severity grade of COVID-19. They include complement factors, the coagulation system, inflammation modulators, and pro-inflammatory factors upstream and downstream of interleukin 6. All protocols and software for implementing our approach are freely available. In total, this work supports the development of routine proteomic assays to aid clinical decision making and generate hypotheses about potential COVID-19 therapeutic targets.

SUBMITTER: Messner CB

PROVIDER: S-EPMC7264033 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection.

Messner Christoph B CB Demichev Vadim V Wendisch Daniel D Michalick Laura L White Matthew M Freiwald Anja A Textoris-Taube Kathrin K Vernardis Spyros I SI Egger Anna-Sophia AS Kreidl Marco M Ludwig Daniela D Kilian Christiane C Agostini Federica F Zelezniak Aleksej A Thibeault Charlotte C Pfeiffer Moritz M Hippenstiel Stefan S Hocke Andreas A von Kalle Christof C Campbell Archie A Hayward Caroline C Porteous David J DJ Marioni Riccardo E RE Langenberg Claudia C Lilley Kathryn S KS Kuebler Wolfgang M WM Mülleder Michael M Drosten Christian C Suttorp Norbert N Witzenrath Martin M Kurth Florian F Sander Leif Erik LE Ralser Markus M

Cell systems 20200602 1

The COVID-19 pandemic is an unprecedented global challenge, and point-of-care diagnostic classifiers are urgently required. Here, we present a platform for ultra-high-throughput serum and plasma proteomics that builds on ISO13485 standardization to facilitate simple implementation in regulated clinical laboratories. Our low-cost workflow handles up to 180 samples per day, enables high precision quantification, and reduces batch effects for large-scale and longitudinal studies. We use our platfor ...[more]

PMID: 32619549

Similar Datasets

Project description:The urgent need for diagnostics and therapeutics against the COVID-19 pandemic has shown the great potential of antibodies, proteomics and metabolomics in this direction. Several clinical trials are underway using antibodies from COVID-19 patients that show very specific and strong binding to viral proteins leading to neutralization. On the other hand, proteomic and metabolomic profiles of COVID-19 patients present novel diagnostic biomarkers to predict patient outcomes and enable the development of personalized therapeutics to target the dysregulated pathways, as revealed by those profiles. Here, we discuss how studies based on antibodies, proteomics and metabolomics contribute to the development of diagnostics and therapeutics against COVID-19. The elegant technology can extend to high-throughput, rapid and reliable drug discovery strategies of the future. Lay abstract In order to prevent and treat the ongoing COVID-19 pandemic, several groups around the world are focused on a detailed understanding of the biology of SARS-CoV-2 infection, the biological events occurring inside the patients and the response of the patients to the infection. SARS-CoV-2 is the coronavirus that causes COVID-19. Some of the approaches to combat the pandemic have provided important results that can help toward therapeutic developments against COVID-19. This review discusses three such areas – antibody treatment to prevent COVID-19 infection, analysis of changes in protein profiles of COVID-19 patients, and analysis of metabolism or energy-related changes in COVID-19 patients. Antibodies are molecules produced in the host’s body as a defense response to infection. Antibodies extracted from patients who recovered from COVID-19 have been used to successfully manufacture large amounts of antibodies to treat COVID-19 patients. The analysis of protein and metabolism profiles of COVID-19 patients has shown that several proteins and metabolism-related entities in the body are either upregulated or downregulated in COVID-19. These abnormal levels can either be attenuated by medical intervention or can be monitored as indicators of COVID-19 diagnosis. Overall, antibodies, protein and metabolism profiles are three important tools, among several others, that are helpful in combating the COVID-19 pandemic.

Dataset Information

Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection.

Publications

Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets